GH Research PLC
NASDAQ:GHRS
Intrinsic Value
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. [ Read More ]
The intrinsic value of one GHRS stock under the Base Case scenario is 4.27 USD. Compared to the current market price of 12 USD, GH Research PLC is Overvalued by 64%.
Valuation Backtest
GH Research PLC
Run backtest to discover the historical profit from buying and selling GHRS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
GH Research PLC
Current Assets | 164.1m |
Cash & Short-Term Investments | 161.6m |
Other Current Assets | 2.5m |
Non-Current Assets | 62.2m |
Long-Term Investments | 61.1m |
PP&E | 1.1m |
Current Liabilities | 6.7m |
Accounts Payable | 3.5m |
Other Current Liabilities | 3.2m |
Non-Current Liabilities | 631k |
Long-Term Debt | 631k |
Earnings Waterfall
GH Research PLC
Revenue
|
0
USD
|
Operating Expenses
|
-41.2m
USD
|
Operating Income
|
-41.2m
USD
|
Other Expenses
|
5.6m
USD
|
Net Income
|
-35.6m
USD
|
Free Cash Flow Analysis
GH Research PLC
GHRS Profitability Score
Profitability Due Diligence
GH Research PLC's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
Score
GH Research PLC's profitability score is 34/100. The higher the profitability score, the more profitable the company is.
GHRS Solvency Score
Solvency Due Diligence
GH Research PLC's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
GH Research PLC's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GHRS Price Targets Summary
GH Research PLC
According to Wall Street analysts, the average 1-year price target for GHRS is 32.64 USD with a low forecast of 18.18 USD and a high forecast of 42 USD.
Shareholder Return
GHRS Price
GH Research PLC
Average Annual Return | -4.9% |
Standard Deviation of Annual Returns | 77.46% |
Max Drawdown | -81% |
Market Capitalization | 624.3m USD |
Shares Outstanding | 52 026 300 |
Percentage of Shares Shorted | 9.77% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
GH Research Plc operates as a holding company which through its subsidiaries provides biopharmaceutical products and services. The company is headquartered in Dublin, Leinster and currently employs 9 full-time employees. The company went IPO on 2021-06-25. The firm is engaged in offering treatment for psychiatric and neurological disorders. The company focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The firm is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.
Contact
IPO
Employees
Officers
The intrinsic value of one GHRS stock under the Base Case scenario is 4.27 USD.
Compared to the current market price of 12 USD, GH Research PLC is Overvalued by 64%.